Ask AI
ProCE Banner Activity

TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

Podcast Episodes

Listen to experts Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer.

Released: November 19, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Benjamin Levy, MD, FASCO: consultant/advisor/speaker: AstraZeneca, DSI, Janssen, Merck, Pfizer.

Alex Spira, MD, PhD, FASCO: consultant/advisor/speaker: Boehringer Ingelheim, Johnson & Johnson.